Robert Wasserman
Stock Analyst at Benchmark
(2.31)
# 1,457
Out of 4,667 analysts
108
Total ratings
38.82%
Success rate
-0.18%
Average return
Main Sectors:
Stocks Rated by Robert Wasserman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANEB Anebulo Pharmaceuticals | Reiterates: Speculative Buy | $8 | $1.52 | +426.32% | 6 | Nov 19, 2024 | |
| OABI OmniAb | Reiterates: Buy | $8 | $3.80 | +110.53% | 7 | Nov 14, 2024 | |
| NEPH Nephros | Reiterates: Speculative Buy | $5 | $1.59 | +214.47% | 3 | Nov 12, 2024 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $110 → $135 | $111.20 | +21.40% | 9 | Nov 8, 2024 | |
| EBS Emergent BioSolutions | Maintains: Buy | $8 → $12 | $8.76 | +37.06% | 17 | Nov 7, 2024 | |
| ABCL AbCellera Biologics | Reiterates: Hold | n/a | $2.71 | - | 5 | Nov 5, 2024 | |
| CDXS Codexis | Reiterates: Hold | n/a | $4.43 | - | 7 | Nov 4, 2024 | |
| ITGR Integer Holdings | Reiterates: Buy | $140 | $132.93 | +5.32% | 9 | Oct 25, 2024 | |
| IPA ImmunoPrecise Antibodies | Maintains: Speculative Buy | $5 → $3 | $0.38 | +683.29% | 5 | Aug 14, 2024 | |
| TECH Bio-Techne | Reiterates: Buy | $95 | $68.48 | +38.73% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $60 | $45.53 | +31.80% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $135.73 | - | 3 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $12 | $2.93 | +309.56% | 6 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $45 | $37.73 | +19.27% | 6 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $25 | $23.70 | +5.49% | 5 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $1.09 | +267.48% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $0.94 | +325.58% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $75 | $1.56 | +4,723.15% | 2 | Apr 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $231.97 | - | 3 | Oct 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $580 | $510.51 | +13.61% | 1 | Jul 16, 2021 |
Anebulo Pharmaceuticals
Nov 19, 2024
Reiterates: Speculative Buy
Price Target: $8
Current: $1.52
Upside: +426.32%
OmniAb
Nov 14, 2024
Reiterates: Buy
Price Target: $8
Current: $3.80
Upside: +110.53%
Nephros
Nov 12, 2024
Reiterates: Speculative Buy
Price Target: $5
Current: $1.59
Upside: +214.47%
Ligand Pharmaceuticals
Nov 8, 2024
Maintains: Buy
Price Target: $110 → $135
Current: $111.20
Upside: +21.40%
Emergent BioSolutions
Nov 7, 2024
Maintains: Buy
Price Target: $8 → $12
Current: $8.76
Upside: +37.06%
AbCellera Biologics
Nov 5, 2024
Reiterates: Hold
Price Target: n/a
Current: $2.71
Upside: -
Codexis
Nov 4, 2024
Reiterates: Hold
Price Target: n/a
Current: $4.43
Upside: -
Integer Holdings
Oct 25, 2024
Reiterates: Buy
Price Target: $140
Current: $132.93
Upside: +5.32%
ImmunoPrecise Antibodies
Aug 14, 2024
Maintains: Speculative Buy
Price Target: $5 → $3
Current: $0.38
Upside: +683.29%
Bio-Techne
Aug 13, 2024
Reiterates: Buy
Price Target: $95
Current: $68.48
Upside: +38.73%
Aug 8, 2024
Reiterates: Buy
Price Target: $60
Current: $45.53
Upside: +31.80%
Aug 5, 2024
Reiterates: Hold
Price Target: n/a
Current: $135.73
Upside: -
Jul 11, 2024
Reiterates: Speculative Buy
Price Target: $12
Current: $2.93
Upside: +309.56%
May 29, 2024
Reiterates: Buy
Price Target: $45
Current: $37.73
Upside: +19.27%
May 13, 2024
Upgrades: Buy
Price Target: $25
Current: $23.70
Upside: +5.49%
Mar 7, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $1.09
Upside: +267.48%
Mar 6, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $0.94
Upside: +325.58%
Apr 6, 2023
Reiterates: Speculative Buy
Price Target: $75
Current: $1.56
Upside: +4,723.15%
Oct 24, 2022
Downgrades: Hold
Price Target: n/a
Current: $231.97
Upside: -
Jul 16, 2021
Initiates: Buy
Price Target: $580
Current: $510.51
Upside: +13.61%